Acute Promyelocytic Leukemia Rapidly Diagnosed by Immunostaining
By LabMedica International staff writers Posted on 24 Dec 2013 |
Image: Bone marrow smear from a patient with hypergranular acute promyelocytic leukemia (Photo courtesy of the Armed Forces Institute of Pathology).
Antipromyelocytic leukemia (PML) immunofluorescence staining is a known diagnostic tool for rapid diagnosis of acute promyelocytic leukemia (APL).
Recently developed and commercially available, tetramethylrhodamine-5-isothiocyanate–labeled PG-M3 anti-PML antibody for APL diagnosis has been tested in a clinical setting.
A team of scientists at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) used immunofluorescence staining with the tetramethylrhodamine-5-isothiocyanate–labeled PG-M3 antibody to detect PML-retinoic acid receptor alpha (RARA) in bone marrow aspirate and/or peripheral blood smears from 30 patients with acute leukemia between February 1, 2011, and March 31, 2012. The results were compared with those of concurrent testing with our in-house polyclonal anti-PML antibody and with established tests.
For immunofluorescence staining, they used the tetramethylrhodamine-5-isothiocyanate (TRITC)-conjugated anti-PML monoclonal antibody PG-M3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). All APL cases showed a positive, fine and/or microgranular, immunofluorescence staining pattern, whereas non-APL cases showed a negative, chunky and/or macrogranular pattern. These results, which were available within two hours, were validated by testing with the polyclonal anti-PML antibody and with established cytogenetic and molecular testing methods.
The authors concluded that they had validated the utility of the TRITC–labeled anti-PML antibody PG-M3 for the diagnosis of APL. Their results indicate that immunofluorescence staining with this antibody is a rapid and reliable method for the diagnosis of APL. The study was published on in the journal Archives of Pathology & Laboratory Medicine.
Related Links:
The University of Texas MD Anderson Cancer Center
Santa Cruz Biotechnology
Recently developed and commercially available, tetramethylrhodamine-5-isothiocyanate–labeled PG-M3 anti-PML antibody for APL diagnosis has been tested in a clinical setting.
A team of scientists at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) used immunofluorescence staining with the tetramethylrhodamine-5-isothiocyanate–labeled PG-M3 antibody to detect PML-retinoic acid receptor alpha (RARA) in bone marrow aspirate and/or peripheral blood smears from 30 patients with acute leukemia between February 1, 2011, and March 31, 2012. The results were compared with those of concurrent testing with our in-house polyclonal anti-PML antibody and with established tests.
For immunofluorescence staining, they used the tetramethylrhodamine-5-isothiocyanate (TRITC)-conjugated anti-PML monoclonal antibody PG-M3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). All APL cases showed a positive, fine and/or microgranular, immunofluorescence staining pattern, whereas non-APL cases showed a negative, chunky and/or macrogranular pattern. These results, which were available within two hours, were validated by testing with the polyclonal anti-PML antibody and with established cytogenetic and molecular testing methods.
The authors concluded that they had validated the utility of the TRITC–labeled anti-PML antibody PG-M3 for the diagnosis of APL. Their results indicate that immunofluorescence staining with this antibody is a rapid and reliable method for the diagnosis of APL. The study was published on in the journal Archives of Pathology & Laboratory Medicine.
Related Links:
The University of Texas MD Anderson Cancer Center
Santa Cruz Biotechnology
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data